Enoximone

Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.Perioperative Enoximone administration improved renal function in patients undergoing on-pump cardiac surgery. (In Vitro) :In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils. (In Vivo) :Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM) -induced allergic airway inflammation.The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.